INVESTOR PORTAL
Information for current and prospective investors in TRANSCENDENCE.
Last updated: January 1, 2025
Company Overview
TRANSCENDENCE is pioneering the integration of biological age reversal protocols with artificial general intelligence. Our mission is to solve aging and enhance human capability through cutting-edge biotechnology and AI systems.
Investment Opportunity
We are currently accepting qualified investors for our Series B funding round. Minimum investment thresholds and accreditation requirements apply. Contact our investor relations team for detailed information.
Key Metrics
Our protocol has demonstrated measurable biological age reversal averaging 27 years across our initial cohort. Current valuation and growth projections are available to qualified investors under NDA.
Due Diligence
Comprehensive due diligence materials, including scientific data, financial projections, and regulatory pathway documentation, are available to serious investors who pass our initial screening.
Contact Investor Relations
To learn more about investment opportunities, please contact our investor relations team at investors@transcendence.io. All inquiries are treated with strict confidentiality.
All investment inquiries are treated with strict confidentiality.